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Abstract
Background: There is strong evidence implicating eosinophils in host defence against parasites as
well as allergic disease pathologies. However, a lack of reagents such as monoclonal antibodies
(mAbs) specific for eosinophils has made it difficult to confirm the functional role of eosinophils in
such disease conditions. Using an established mammary model of allergic inflammation in sheep,
large numbers of inflammatory cells enriched for eosinophils were collected from parasite-
stimulated mammary glands and used for the generation of mAbs against ovine eosinophils.
Results: A panel of mAbs was raised against ovine eosinophils of which two were shown to be
highly specific for eosinophils. The reactivity of mAbs 3.252 and 1.2 identified eosinophils from
various cell and tissue preparations with no detectable reactivity on cells of myeloid or lymphoid
lineage, tissue mast cells, dendritic cells, epithelial cells or other connective tissues. Two other
mAbs generated in this study (mAbs 4.4 and 4.10) were found to have reactivity for both
eosinophils and neutrophils.
Conclusion: This study describes the production of new reagents to identify eosinophils (as well
as granulocytes) in sheep that will be useful in studying the role of eosinophils in disease pathologies
in parasite and allergy models.
Background
Eosinophils have been proposed to play various roles in
homeostasis, ranging from their involvement in tissue
development to directing or facilitating innate and adap-
tive immune responses [1]. There is also a great body of
evidence implicating eosinophils as central effector cells
in parasitic and allergic disease. While there is sound evi-
dence that demonstrates the contribution of eosinophils
to host defence against parasitic infections [1,2], contro-
versy still remains regarding the functional role(s) played
by eosinophils in allergic diseases such as asthma [1]. This
is largely based on inconsistencies between work in ani-
mal models and the human disease and the inability to
effectively target eosinophils. For example, clinical resolu-
tion of human asthma could not be demonstrated by tar-
geting eosinophils with anti-IL-5 therapy [3], despite the
many studies in animal models that have shown the suc-
cess of IL-5 neutralization in blocking experimental
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asthma [4-6]. It has subsequently been shown that path-
ways independent of IL-5 are relevant for eosinophil
development or recruitment to sites of allergic inflamma-
tion [7].
The study of eosinophils in parasitic and allergic diseases
has relied largely on the use of cytochemical stains that
react with distinctive basic cytoplasmic granules of the
eosinophil. Granule release or degranulation that com-
monly follows eosinophil recruitment into inflamed tis-
sues, however, often limits use of cytochemical stains for
the study of eosinophils.
In recent years, the use of monoclonal antibodies (mAbs)
has been applied to the study of eosinophils and their
functional role both in vivo and ex vivo. Eosinophils are
known to express a range of membrane receptors enabling
cell-cell communication, including receptors for adhesion
molecules, immunoglobulins and soluble mediators such
as cytokines and chemokines [1]. Some mAbs shown to
be useful for identifying eosinophils, though not entirely
specific for eosinophils, have included the IL-5 receptor,
chemokine receptor-3 (CCR3) and the basic granule pro-
teins, major basic protein (MBP) and eosinophil cationic
protein (ECP) [1].
Sheep are the natural host to a range of helminthic para-
sites and therefore represent a relevant model to study the
role of eosinophils in parasite immunity [8]. Sheep mod-
els of allergic inflammation have also been used for the
study of eosinophils [9,10]. As in other species, ovine
eosinophils have been shown to express a range of leuko-
cyte surface markers including CD11a, CD11b, CD11c,
CD18, CD29, CD44, CD45, CD49, and CD62L [9-11].
However, none of these proteins are expressed exclusively
by eosinophils and to date, there are no mAbs that iden-
tify eosinophils in isolation in any species.
Given the close lineage relationship of granulocytes it is
not surprising that a number of mAbs raised against cell
surface components of eosinophils also show reactivity
with other granulocytes. Most recently, Siglec-8 was
reported to be the first identified eosinophil-exclusive sur-
face receptor [12], however, a subsequent report demon-
strated expression on basophils and mast cells [13]. Other
examples include mAbs directed against eosinophil MBP
and ECP that are also reactive with other granulocyte pop-
ulations [14]. A major impediment to the generation of
eosinophil-exclusive mAbs has been the inherent diffi-
culty in gaining access to reasonable numbers of eosi-
nophils of sufficient purity. The aim of this study was to
use a sheep model of allergic inflammation to source large
numbers of eosinophils and use these for the generation
of mAbs specific for ovine eosinophils.
Results
Preparation of purified eosinophils
Eosinophils used for mAb production and screening were
sourced from sheep mammary glands that were primed
and stimulated with Haemonchus contortus L3 larvae. Dif-
ferential cell counts of cytospots showed that mammary
lavage (MAL) cells consisted of mostly eosinophils (80%),
Enrichment of eosinophils from mammary lavage leukocytes Figure 1
Enrichment of eosinophils from mammary lavage leukocytes. Mammary lavage leukocytes obtained 72 h post chal-
lenge with Haemonchus contortus L3 larvae. (A) Cytospin preparation of MAL cells stained with Wright's stain, showing mostly 
eosinophils (~80%; arrows) and lower number of lymphocytes (5–10%) and macrophages (10–15%). (B) The three populations 
of leukocytes in MAL were resolved on the basis of forward scatter (FSC) versus side scatter (SSC).G1, eosinophils. G2, lym-
phocytes. G3, macrophages. (C) Cytospin preparation showing eosinophils which were gated and collected as in (B; G1) result-
ing in a highly enriched population of eosinophils (about 98%).
G1
G3
Forward scatter (FSC)
S
i
d
e
 
s
c
a
t
t
e
r
 
(
S
S
C
) A B C
G2BMC Immunology 2007, 8:23 http://www.biomedcentral.com/1471-2172/8/23
Page 3 of 10
(page number not for citation purposes)
lymphocytes (10%) and macrophages (10%) (Figure 1A).
MAL cells analysed by flow cytometry appeared as three
distinct cell populations distinguished on the basis of
their forward scatter (FSC) and side scatter (SSC) proper-
ties (Figure 1B), enabling mAbs to be screened for reactiv-
ity with the gated cell populations. The gated eosinophil
population (Figure 1B; G1) was sorted using a flow cytom-
eter and analysis of cytospins confirmed the high purity
(>98%) of eosinophils (Figure 1C).
Selection of monoclonal antibodies reactive with ovine 
eosinophils
MAbs reactive with sheep eosinophils were generated fol-
lowing mouse immunisations with preparations of eosi-
nophil soluble lysate, granule extract, or whole live sorted
cells.
Two fusions were performed from mice immunised with
the soluble lysate and resulting hybridoma cell superna-
tants screened against eosinophil and neutrophil soluble
lysates by Western blot. The mAb 1.2 (IgG1 istoype) was
selected as it showed reactivity with eosinophils but not
neutrophils.
Following fusions of spleen cells from mice immunised
with eosinophil granule extracts, hybridoma supernatants
were screened against eosinophil and neutrophil granule
extracts by Western blot and eosinophil and neutrophil
MAL cytospots by immunocytohemistry. Two clones reac-
tive with eosinophils and neutrophils, designated mAb
4.4 (IgG1) and mAb 4.10 (IgG1), were characterised as
granulocyte-specific markers.
A total of three fusions were performed with mouse
spleen cells following immunisation of mice with whole
eosinophils. Hybridoma supernatants were screened
against MAL cells by flow cytometry and mAb 3.252
(IgG1) was chosen for its reactivity with eosinophils.
Surface and intracellular staining of leukocytes with 
monoclonal antibodies against ovine eosinophils
Flow cytometry was used to assess whether the mAbs gen-
erated were reactive with cell surface or intracellular mol-
ecules (summary presented in Table 1). Furthermore, by
gating on individual leukocyte populations within blood
and MAL, the specificity of the mAbs was analysed. Reac-
tivity was measured by the percentage positive reactivity
relative to that observed with an isotype-matched control
mAb, and the relative mean fluorescence intensity
(RMFI).
MAb 1.2 showed no surface staining of any of the gated
cell populations in peripheral blood or MAL including
eosinophils (Figure 2A) and neutrophils (Figure 2B) when
compared to an isotype matched control. However, fol-
lowing permeabilisation of cells to detect intracellular
reactivity, mAb 1.2 showed clear positive intracellular
staining of blood and MAL eosinophils (Figure 2C;
>90%), but not neutrophils (Figure 2D), lymphocytes,
monocytes or macrophages from peripheral blood,
Flow cytometrical analysis of mAb reactivity with eosinophils and neutrophils Figure 2
Flow cytometrical analysis of mAb reactivity with eosinophils and neutrophils. Flow cytometrical analysis of eosi-
nophils and neutrophils stained for surface and intracellular expression with (A-D) mAb 1.2, (E-H) mAb 3.252 and (I, J) mAb 
4.4. Positive staining is represented in each plot by a solid histogram while the reactivity with an isotype-matched control mAb is 
represented by an open histogram. Profiles shown are representative of three separate experiments.
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lymph node, MAL and bronchoalveolar lavage (BAL)
samples (not shown).
In contrast, mAb 3.252 showed weak surface staining of
MAL eosinophils (Figure 2E) and following permeabilisa-
tion greater than 98% of eosinophils showed intracellular
staining (Figure 2G). Exclusive reactivity with eosinophils
was confirmed by gating neutrophils (Figure 2F&H), lym-
phocytes, monocytes and macrophages from peripheral
blood, lymph node, MAL and BAL samples which were
unstained both on their surface and intracellularly (data
not shown).
Expression of the antigen(s) identified by the mAbs 1.2
and 3.252 did not appear to be affected by eosinophil
maturation and/or activation status as there was no
change in staining intensity observed comparing eosi-
nophils collected from bone marrow, peripheral blood
and MAL (not shown).
The reactivity of the granulocyte mAbs (4.4 and 4.10) was
examined on leukocytes in MAL and peripheral blood by
flow cytometry. The mAb 4.4 showed no surface staining
of cells, however, there was positive intracellular staining
seen with both eosinophils (Figure 2I) and neutrophils
(Figure 2J), with stronger relative staining apparent in
neutrophils. In contrast, mAb 4.10 did not appear to show
any reactivity with leukocytes by flow cytometry.
Immunocytochemical staining and tissue distribution of 
eosinophils reactive with monoclonal antibodies 1.2 and 
3.252
The tissue distribution of eosinophils reactive with the
mAbs 1.2 and 3.252 was assessed by immunocytochemis-
try on cytospin preparations and in tissues (summary pre-
sented in Table 1). Cytospin preparations of peripheral
blood and MAL leukocytes confirmed the pattern of reac-
tivity observed by flow cytometry (Figure 3). Peripheral
blood and MAL eosinophils showed intense intracellular
staining with the mAbs 1.2 (Figure 3C&D) and 3.252 (Fig-
ure 3E&F) while all other leukocytes were unstained. In
contrast, the granulocyte-specific mAbs 4.4 and 4.10
showed intense staining of peripheral blood eosinophils
and neutrophils in peripheral blood (Figure 3G) and MAL
(Figure 3H).
Sheep tissues displaying high eosinophil levels due to par-
asite or allergic challenge (Figure 4) were sectioned and
stained for reactivity with the mAbs 1.2 and 3.252. Lung
tissue was collected following allergen challenge while
abomasal (gut) and associated lymph node tissues were
obtained from a gastrointestinal parasite infected sheep.
Both mAbs showed optimal staining when tissues were
fixed in ethanol, compared with paraformaldehyde or for-
malin. MAb 3.252 stained eosinophils equally well on
frozen and paraffin embedded tissues, while staining with
mAb 1.2 was optimal on frozen sections. Positive staining
identified eosinophils in each of the tissues examined,
with other leukocytes and tissue components unstained
(Figure 4). However, staining with mAb 1.2 in many cases
appeared more diffuse compared to reactivity seen with
mAb 3.252. There did not appear to be any evidence of
reactivity with tissue mast cells or basophils in normal or
pathological tissues.
Cross reactivity of mAbs 1.2 and 3.252 with eosinophils
from other species was assessed on cell and tissue prepa-
rations (normal and pathological) by immunocytochem-
istry. Both mAbs showed cross-reactivity with goat
peripheral blood eosinophils while the mAb 3.252 also
recognised cow eosinophils. No reactivity was detected
with either mAb in cell and tissue samples sourced from
murine (peripheral blood and various organs sourced
from IL-5 transgenic mice) or human (peripheral blood
and asthmatic airways) subjects.
Western blot analysis with eosinophil-specific monoclonal 
antibodies
The reactivity of the mAbs as assessed by Western blot
analysis is summarised in Table 1. No reactivity of the
mAb 3.252 was detected by Western blot. In contrast,
Western blotting was used in the screening and selection
Table 1: Reactivity of ovine granulocyte-specific monoclonal antibodies
Antibody reactivity§ Cell reactivity
mAb Isotype WB Flow cytometry IHC eosinophil neutrophil
1.2 IgG1 ++1 ++ (ic) ++ (cy,F) ++ -
3.252 IgG1 - ++ (su,ic) ++ (cy,F,P) ++ -
4.4 IgG1 ++2 ++ (ic) ++ (cy,F) + ++
4.10 IgG1 ++2 - ++ (cy,F) + ++
§ Western blot (WB) analysis (1reactivity detected on whole cell extracts; 2reactivity detected on eosinophil soluble and granule lysates); Flow 
cytometry analysis for surface (su) and intracellular (ic) reactivity; Immunohistochemistry (IHC) performed on cytospots (cy), and frozen (F) and 
paraffin-embedded (P) tissue sections fixed in 95% ethanol.
- no reactivity; + moderate reactivity; ++ strong reactivityBMC Immunology 2007, 8:23 http://www.biomedcentral.com/1471-2172/8/23
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of mAb 1.2 and could therefore be used to characterise the
molecules recognised by mAb 1.2 in different sample
preparations (Figure 5). Whole cell extracts from relatively
pure (>80%) preparations of eosinophils, neutrophils,
lymphocytes and macrophages were analysed by Western
blot under reducing conditions. Extracts were prepared
from an equal number of cells and identical blots probed
with either mAb 1.2 or a negative control mAb. The eosi-
nophil whole cell extract showed reactivity with a band of
approximately 75 kDa, while no reactivity was detected in
neutrophil, lymphocyte or macrophage extracts (Figure
5). Western blot analysis of the granulocyte-specific mAbs
4.4 and 4.10 showed reactivity with multiple bands (24–
80 kDa) in eosinophil soluble and granule lysate prepara-
tions (not shown).
Discussion
In the present study, we employed a sheep model of
inflammation to provide access to large numbers of rela-
tively pure eosinophils [9,15], required for mAb produc-
tion and characterisation. Mice were immunised with
either whole eosinophils, eosinophil soluble lysate or
granule extract and the resulting mAbs were selected on
the basis of their reactivity with eosinophils. These studies
produced a panel of mAbs with reactivity for eosinophils
alone (mAbs 1.2 and 3.252) and both eosinophils and
neutrophils (mAbs 4.4 and 4.10).
The first eosinophil specific mAb 3.252 produced recog-
nises eosinophils in bone marrow, peripheral blood and
the inflamed mammary gland compartment, both by flow
cytometry and immunocytochemistry. In fact, following
their recruitment in response to allergic stimuli, all eosi-
nophils (>98%) were stained by this mAb. Selection of
mAb 3.252 was based on surface reactivity of mammary
lavage (MAL) eosinophils, although the reactive protein
was subsequently shown (by flow cytometry) to be
present both on the cell surface and intracellularly. It is
not uncommon for intracellular molecules to also be
detected on the surface of cells, as has been shown to be
the case with eosinophil derived neurotoxin (EDN), pre-
viously considered to be intracellular but recently identi-
fied at low levels on the surface of eosinophils [16]. The
exclusive reactivity of mAb 3.252 at comparable levels on
all eosinophils at different tissue sites suggests that this
mAb would be suitable as a diagnostic tool for the dis-
crimination of eosinophils in sheep.
The second eosinophil-specific mAb, mAb 1.2, proved
useful for the discrimination of eosinophils by flow
cytometry and immunocytochemical staining. There was
little variation in the level of staining when comparing
cells from bone marrow, blood and MAL, although in
contrast to mAb 3.252, not all eosinophils stained posi-
tive with the mAb 1.2. A consistent, albeit small (5–10%),
population of unstained cells was seen in all sites tested.
Further, the 75 kDa protein identified in eosinophil
lysates by mAb 1.2 could not be detected by Western blot
in MAL fluid following eosinophil recruitment or in vitro
in the culture supernatant of eosinophils stimulated to
degranulate as measured by eosinophil peroxidase release
(data not shown), suggesting the protein is not being
released by eosinophils. This is in contrast to galectin-14,
an exclusive product of eosinophils, which is released into
the brochoalveolar (BAL) fluid after allergen challenge
[17].
Immunocytochemical staining of peripheral blood and mam- mary lavage cells with granulocyte-specific mAbs Figure 3
Immunocytochemical staining of peripheral blood 
and mammary lavage cells with granulocyte-specific 
mAbs. Cytospin preparations of peripheral blood and MAL 
leukocytes were stained with Wright's stain and mAbs 1.2, 
3.252 and 4.10. (A, B) Cytospots stained with Wright's stain 
alone show the presence of eosinophils in peripheral blood 
and MAL. Positive staining of eosinophils (arrows) but not 
other leukocytes was seen with (C, D) mAb 1.2 and (E, F) 
mAb 3.252. MAb 4.10 showed intense staining (arrows) of 
eosinophils and neutrophils in (G) blood and (H) MAL cell 
preparations. Bound antibody was detected using the indirect 
immunoperoxidase technique, followed by weak H&E stain-
ing (Original magnification ×40).
         Peripheral blood          MAL fluid
B A
D C
F E
G HBMC Immunology 2007, 8:23 http://www.biomedcentral.com/1471-2172/8/23
Page 6 of 10
(page number not for citation purposes)
The application of mAb 3.252 and mAb 1.2 for immuno-
cytochemistry allowed eosinophils to be detected in vari-
ous tissues. Strong reactivity was detected in frozen tissue
sections, while in fixed paraffin-embedded tissues, posi-
tive staining was detected after ethanol fixation but not
with the use of formaldehyde-based fixatives. The wide-
spread use of mAbs to identify eosinophils has included
antibodies reactive with the IL-5 receptor, CC chemokine
receptor-3 (CCR3) and the granule proteins MBP and ECP
[1]. However, none of these markers are expressed exclu-
sively by eosinophils. With the mAbs generated in the
present study, and our earlier report describing a novel
eosinophil-specific galectin [17], sheep are to date the
only species in which eosinophil exclusive mAbs are avail-
able.
The identity of the antigens reactive with the eosinophil-
specific mAbs generated in the present study is yet to be
determined. The major constituents of the secondary
granules, generally low molecular weight proteins, are
amongst the best-characterised intracellular proteins of
the eosinophil. These include the cytotoxic cationic gran-
ule proteins, as well as an array of pro-inflammatory
cytokines, chemokines and lipid mediators [1]. It was
found that mAb 1.2 identified a protein band at 75 kDa in
eosinophil lysates, much greater than the molecular
Immunocytochemistry of ovine tissues stained with eosinophil-specific mAbs Figure 4
Immunocytochemistry of ovine tissues stained with eosinophil-specific mAbs. Tissue-infiltrating eosinophils were 
observed in frozen tissue sections following H&E staining in (A) lung tissue collected 48 h post-HDM allergen challenge, and (B) 
abomasum and (C) associated lymph node taken from a parasite-infected sheep. Immunoperoxidase staining of near serial tis-
sue sections of lung, abomasum and lymph node with (D, E, F) mAb 1.2 and (G, H, I) mAb 3.252 shows staining associated with 
infiltrating eosinophils in each of the tissues examined (see arrows). Note the diffuse brown positive staining observed with 
mAb 1.2 compared with the more distinct reactivity of mAb 3.252. Higher magnification insets (in D and G) show detail of pos-
itively-stained eosinophils in allergen-challenged lung tissues.
   Lung  Abomasum    Lymph node 
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weight of known granule components. It seems that both
mAb 1.2 and 3.252 do not react with specific granules but
as yet unidentified eosinophil constituents. The identifi-
cation of these antigens, a current focus in our laboratory,
will be required to characterise the role of these molecules
in eosinophil-associated pathologies.
The mAbs generated in the present studies will assist the
study of ruminant eosinophils ex vivo and in vivo. With the
use of appropriate models of parasite and allergic disease,
these mAbs may be shown to be effective for the inhibi-
tion of eosinophils or their effector functions, and con-
tribute to our understanding of the role of eosinophils in
protection against infection and disease pathology.
Conclusion
In this study, two mAbs that identify sheep eosinophil
and neutrophil granules and two eosinophil exclusive
mAbs have been produced. The mAbs 1.2 and 3.252 react
with eosinophils but not lymphocytes, monocytes, neu-
trophils or macrophages. An eosinophil exclusive mAb
has great potential as a tool for eosinophil research as to
date there are limited reagents available for identifying
eosinophils. Other mAbs generated here were found to be
reactive for both eosinophils and neutrophils (mAbs 4.4
and 4.10). The study of immunological responses of
sheep to parasite infections, where eosinophils are impli-
cated, and in sheep models of allergic inflammation will
now be greatly facilitated by the development of these
eosinophil specific reagents.
Methods
Animals
Mature non-lactating merino ewes (2 years of age) were
purchased from a commercial farm and treated with the
anthelminthic Nilverm™ (Cooper's Animal Health, New
South Wales, Australia) to eliminate any existing parasite
infections. Sheep were housed in pens at the School of
Veterinary Science, The University of Melbourne and fed
dry pellets (Barastoc, Victoria, Australia) and water ad libi-
tum. All experimental procedures and the collection of tis-
sues and cells were approved by the Animal
Experimentation Ethics Committee of The University of
Melbourne, following guidelines set by the National
Health & Medical Research Council (NH&MRC) of Aus-
tralia.
Mammary gland infusions and the collection of mammary 
lavage cells
For the collection of mammary lavage (MAL) leukocytes,
mammary gland infusions were performed as previously
described [9]. Briefly, for eosinophil recruitment into the
gland, non-lactating Merino ewes were primed with
weekly infusions of 5000 exsheathed Haemonchus contor-
tus (Hc) L3 larvae, rested for 3–4 weeks followed by chal-
lenge of the gland with Hc larvae. Cells were retrieved 3
days post challenge with the infusion of sterile pyrogen
free saline (PFS, Baxter Healthcare, New South Wales,
Australia) and milking of the gland. For collection of neu-
trophils, mammary glands were infused with lipopolysac-
charide (LPS) and cells collected 24 h later [15]. Cells were
pelleted by centrifugation and washed in PFS. Cytospots
were prepared and stained with Wright's stain (Sigma,
New South Wales, Australia) to determine the proportion
of eosinophils or neutrophils in the suspension.
Preparation of cell suspensions and tissue samples
Peripheral blood leukocytes (PBL) were collected from the
jugular vein of sheep and placed into a tube containing 80
mM ethylamine tetra-acetic acid-Na2 (EDTA). Cells were
treated with Tris-buffered ammonium chloride (TAC;
0.17 M Tris/0.16 M NH4Cl pH 7.2) to lyse red blood cells.
Lymphocytes were prepared from resected lymph nodes
by gentle teasing with forceps in cold Dulbecco's Modified
Eagles Medium (DMEM; Invitrogen, Life Technologies).
Alveolar macrophages were obtained from bronchoalveo-
lar lavage (BAL) fluid as described previously [10,18].
Eosinophils and neutrophils were prepared from MAL
washings as described earlier.
Western Blot analysis of ovine cell preparations probed with  the eosinophil-specific mAb 1.2 Figure 5
Western Blot analysis of ovine cell preparations 
probed with the eosinophil-specific mAb 1.2. (A) Equal 
numbers of cells (1 × 105) enriched for MAL eosinophils (E), 
MAL neutrophils (N), lymph node (LN) lymphocytes (L) or 
BAL macrophages (M) were subjected to SDS-PAGE under 
reducing conditions followed by Western blot analysis using 
mAb 1.2. (B) Band detected by mAb 1.2 in a MAL eosinophil 
soluble lysate under reducing (SR) and non-reducing (SN) 
conditions.BMC Immunology 2007, 8:23 http://www.biomedcentral.com/1471-2172/8/23
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In each case cells were washed three times in phosphate-
buffered saline (PBS) before being resuspended at 1 × 107
cells/ml in SDS-PAGE reducing buffer and stored frozen
prior to Western blot analysis, or in 2% bovine serum
albumin (BSA, Fraction V; Trace Biosciences, Victoria,
Australia)/PBS for flow cytometry analysis. Purity of the
cell preparations was found to be greater than 80% in
each case, as assessed on cytospots stained with Wright's
stain.
IL-5 transgenic mice, displaying high levels of peripheral
blood and tissue eosinophilia [19], were kindly provided
by Dr. Lindsay Dent (Department of Microbiology and
Immunology, University of Adelaide). Caprine and
bovine peripheral blood for immunocytochemistry was
provided by Dr Stuart Barber (Department of Veterinary
Science, The University of Melbourne). Paraffin-embed-
ded human lung and large airway tissue from an asth-
matic patient were kindly donated by Dr. Alastair Stewart
(Department of Pharmacology, The University of Mel-
bourne).
Preparation of soluble and granule extracts
MAL cells derived from Hc  (eosinophils) or LPS (neu-
trophils) stimulated glands were washed three times in
PBS before being lysed by repeated freeze thaw cycles of 1
× 107 pelleted cells. For the preparation of soluble lysates,
lysed cells were resuspended in PBS and centrifuged at
100,000  g  for 20 min. Granule extracts were prepared
based on previously described methods [20]. Briefly, lysed
cells were centrifuged at 13,000 g for 20 min, and pelleted
granules exposed to 0.01 M HCl (pH 2) followed by son-
ication and final centrifugation (40,000 g for 20 min) to
remove the released granule proteins from the insoluble
material. Protein concentration of the resulting superna-
tants was determined using the bicinchoninic acid (BCA)
assay (Pierce, Illinois, USA) and aliquots consisting of 10
µg and 50 µg of protein were stored at -20°C prior to mice
immunisations. Identical extracts were separated by SDS-
PAGE for hybridoma supernatant screening by Western
blot analysis.
Production of monoclonal antibodies
For the production of monoclonal antibodies (mAbs), 3
groups of BALB/c mice were immunised intraperitoneally
(i.p.) with eosinophil preparations. Group 1 mice
received 10 µg of eosinophil soluble extract in complete
Freund's complete adjuvant (CFA; Sigma). Group 2 mice
received 10 µg of eosinophil granule extract in CFA. The
third group of mice (group 3) received an eosinophil rich
preparation consisting of 2 × 107 MAL cells (~80–98%
pure eosinophils) in 500 µl PBS. Subsequent injections
were given at monthly intervals. Six weeks following the
third immunisation, mice received 50 µg of protein (solu-
ble lysate/group 1; granule extract/group 2) in PBS or a
100% pure (sorted by flow cytometry) preparation of
eosinophils (group 3) intravenously (i.v.). Spleens were
harvested 4 days following the final i.v. immunisation
and fused with NS-1 myeloma cells using 50% polyethyl-
ene glycol 4000 (Merck, Darmstadt, Germany). Superna-
tants were screened for eosinophil binding by Western
blot analysis (group 1, 2), flow cytometry (group 3 mice)
and immunocytochemical staining of MAL cytospots
(groups 1 and 3). Hybridomas showing reactivity with
eosinophils but not other leukocytes were cloned by lim-
iting dilution at least three times. The isotype of the result-
ant mAbs was determined using a mouse mAb isotyping
kit (Isostrip, Roche Diagnostics, New South Wales, Aus-
tralia).
SDS-PAGE and Western blotting
Hybridoma supernatants obtained following the fusion of
spleens from mice immunised with an eosinophil soluble
or granule extract were screened by Western blot analysis.
Eosinophil and neutrophil extracts were heat denatured in
reducing sample buffer and subjected to SDS-PAGE on
12.5% gels without a gel comb. Cell preparations of eosi-
nophils, lymphocytes, neutrophils and macrophages were
separated by 12.5% SDS-PAGE and transferred to 0.45 µM
nitrocellulose membranes (MSI, Victoria, Australia) by
electroblotting at 100 V for 1 h. For screening hybridoma
supernatants, the membrane was cut into strips prior to
probing. Membranes were incubated with mAb superna-
tant for 1 h, followed by incubation with horseradish per-
oxidase (HRP)-conjugated rabbit anti-mouse Ig (DAKO,
California, USA) for 1 h. Bound conjugate was visualised
using 1.5 mM 3,3'-diaminobenzidine tetrahydrochloride
(DAB; Sigma). Molecular weights were determined using
SeeBlue Plus 2 prestained molecular weight markers (Inv-
itrogen, Life Technologies, Victoria, Australia).
Flow cytometry
Flow cytometry was used to obtain a 100% pure eosi-
nophil preparation from MAL cells by the gating of eosi-
nophils based on their forward scatter (FSC) and side
scatter (SSC) properties. Hybridoma supernatants were
screened approximately two weeks following fusion for
the presence of antibodies by flow cytometry. Flow cytom-
etry was also used for the detection of cell surface and
intracellular molecules on MAL cells and PBLs as previ-
ously described [10,17]. Briefly, cells were incubated with
undiluted mAb supernatants for 30 min at 4°C then cen-
trifuged, washed and incubated with fluorescein isothyo-
cyanate (FITC)-conjugated anti-mouse F(ab')2
immunoglobulin (Silenus, Melbourne, Australia) for 30
min at 4°C. Cells were then washed and fixed in 3% for-
maldehyde in PBS prior to analysis by flow cytometry.
Different leukocyte cell populations were gated out on the
basis of FSC and SSC characteristics and 10,000 events
were analysed using a FACSCaliber™ flow cytometer (Bec-BMC Immunology 2007, 8:23 http://www.biomedcentral.com/1471-2172/8/23
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ton-Dickinson, Mountain View, California, USA) and Cel-
lQuest™ software (Becton-Dickinson). Percentage
reactivity (positive staining) and relative mean fluores-
cence intensity (RMFI) was assessed relative to an isotype-
matched negative control mAb (SBU-3) that does not
react with sheep leukocytes [10].
Immunocytochemistry
For cytospots preparations, blood and MAL cells were
fixed in 95% ethanol for 10 min. Slides were blocked for
endogenous peroxidase by immersion in PBS/0.03%
H2O2 for 10 min then covered with undiluted mAb super-
natant and incubated in a humid box for 1 h at room tem-
perature (RT). Slides were washed in PBS, then incubated
with HRP-conjugated rabbit anti-mouse IgG (DAKO) in
PBS containing 2% normal sheep serum (NSS) for 1 h.
Conjugate antibody was detected by incubating slides
with DAB solution for 10 min. The slides were then coun-
terstained with haematoxylin and eosin Y (H&E; Sigma).
For immunostaining of tissue sections, tissues were either
fixed in 95% cold ethanol then processed to paraffin, or
embedded in Optimal Cutting Temperature (OCT) solu-
tion (Tissue Tek, Miles Inc., USA), snap-frozen in liquid
nitrogen and stored at -70°C. Frozen tissue sections (5
µM) were cut onto glass microscope slides, air-dried and
fixed in 95% ethanol for 10 min. Sections (paraffin and
frozen) were blocked for endogenous peroxidase and
non-specific binding sites were blocked by incubation
with 10% NSS in PBS for 20 min at RT. Undiluted mAb
supernatant was then applied and sections incubated for
60 min at RT, and, after washing in PBS, slides were incu-
bated with biotinylated rabbit anti-mouse Ig (DAKO) for
30 min at RT. Sections were again washed, followed by a
30 min incubation in streptavidin-HRP (Silenus). Sec-
tions were developed with DAB and counterstained with
H&E.
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